Wilmington Savings Fund Society FSB grew its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 801.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,606 shares of the company's stock after buying an additional 16,541 shares during the quarter. Wilmington Savings Fund Society FSB's holdings in Zoetis were worth $3,635,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mizuho Securities USA LLC raised its holdings in shares of Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after purchasing an additional 4,829,815 shares during the last quarter. Sarasin & Partners LLP raised its position in Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company's stock worth $390,682,000 after acquiring an additional 1,904,899 shares during the period. International Assets Investment Management LLC boosted its stake in Zoetis by 41,235.7% in the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company's stock valued at $183,652,000 after acquiring an additional 937,700 shares during the last quarter. Marshall Wace LLP grew its position in shares of Zoetis by 7,608.6% during the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company's stock valued at $144,874,000 after acquiring an additional 824,843 shares during the period. Finally, Holocene Advisors LP bought a new position in Zoetis during the third quarter valued at $110,809,000. Institutional investors and hedge funds own 92.80% of the company's stock.
Zoetis Trading Down 0.3 %
Shares of ZTS traded down $0.48 during trading hours on Friday, hitting $178.36. The company had a trading volume of 1,097,585 shares, compared to its average volume of 2,529,676. The firm has a market cap of $80.47 billion, a P/E ratio of 34.05, a P/E/G ratio of 2.89 and a beta of 0.89. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The stock's 50 day moving average price is $180.82 and its 200 day moving average price is $181.12. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.
Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. The firm had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.36 earnings per share. On average, research analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.
Zoetis Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.12%. This is a boost from Zoetis's previous quarterly dividend of $0.43. Zoetis's payout ratio is 32.33%.
Analyst Upgrades and Downgrades
ZTS has been the subject of several recent research reports. Leerink Partnrs raised Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. UBS Group began coverage on Zoetis in a report on Monday. They issued a "neutral" rating and a $196.00 price target for the company. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price objective for the company. Finally, Stifel Nicolaus boosted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a "buy" rating in a research report on Wednesday, September 18th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $216.70.
Get Our Latest Analysis on ZTS
About Zoetis
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Stories
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
